Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doctor WeeZuhl Does $ELTP need FDA official PADE clearance before $ELTP's filed ANDAs Percocet and Norco can be FDA approved?
Thxs
Excellent news for $ONCS
$TPIV new HOD $3.28. Looking likes it wants to go higher.
Mayo's Knutson; Keith L absolutely inventing rocket science.
Without a doubt IMO also.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 14/480,365, filed Sep. 8, 2014, which is a continuation of U.S. application Ser. No. 12/740,562, filed Aug. 24, 2010, which is a National Stage application under 35 U.S.C. .sctn.371 that claims the benefit of PCT/US2008/081799, filed Oct. 3, 2008, which claims benefit of priority from U.S. Provisional Application Ser. No. 60/984,646, filed on Nov. 1, 2007. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.
Mayo's Knutson; Keith L Three USA Patent Applications:
15/381,454
14/480,365
12/740,562
Most definitely IMO also
$TPIV new HOD $3.29.
Most definitely would mean double digit PPS for $TPIV when the FDA approves TPIV200 as a new BLA with the PPS into the $20s IMO
$TPIV looking good.
$TPIV new HOD $3.28. Several new HOD
Thxs chris20. A lot of work went into developing this new vaccine by the Mayo Clinic. Success will mean that the FDA will approve a new BLA for $TPIV hopefully in 2018.
$ONCS $1.88 New HOD.
IMO the mkt has corrected all that it needs to for $ONCS. On the way back into the $1.90s
Thxs chris20. This is a great 280 person TNBC $TPIV clinical trial all paid for by the US Dept of Defence with a +$13 mil grant thru the Mayo Clinic. $TPIV has several exclusive licenses with the Mayo Clinic.
God willing we are hoping to save many of these 280 women lives with this new TPIV200 vaccine.
$TPIV $3.16 new HODs starting slow ascent with new CEO Peter Hoang. $TPIV new TNBC Clinical Trial underway with first recruit.
Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03012100?term=NCT03012100&rank=1
NCT03012100
$3.16 $TPIV new HOD. +
$1.86 +10% $ONCS new HODs several times today
Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03012100?term=NCT03012100&rank=1
NCT03012100
Thxs LloydDC
Nice.
Anyone able to find a Clinical Trial number ? Please Post
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
https://tapimmune.com/2017/12/tapimmune-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-treating-triple-negative-breast-cancer-funded-by-u-s-department-of-defense/?utm_source=getresponse&utm_medium=email&utm_campaign=investor_alerts&utm_content=%5B%5Brssitem_title%5D%5D
TapImmune, Inc. Presentation Now Available for On-Demand Viewing
PR NEWSWIRE 4:05 PM ET 12/11/2017
Symbol Last Price Change
TPIV 3.11up +0.04 (+1.3%)
QUOTES AS OF 04:00:00 PM ET 12/11/2017
Company invites individual and institutional investors to view presentation at VirtualInvestorConferences.com
JACKSONVILLE, Fla. , Dec. 11, 2017 /PRNewswire/ -- TapImmune Inc.(TPIV) , a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that Peter Hoang, President and Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
LINK: https://tinyurl.com/1207postpr
TapImmune's (TPIV) presentation will be available for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
Potential to be a dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses; durable immune response generated by >90% of vaccinated patients against target
Evaluating lead candidate in four ongoing Phase 2 studies in ovarian cancer and triple-negative breast cancer; additional studies planned for HER2+ breast cancer vaccine
Capital efficient clinical strategy: two studies fully funded by grants totaling approx. $17 million
PolyStartâ„¢ antigen expression technology offers multiple out-licensing opportunities
Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Department of Defense
That is Nasrat Hakim and Eugene Pfeifer's offical responsibility on behalf of (1) $ELTP the company and (2) $ELTP's shareholders.
Looking for Gottlieb to walk the talk and take action immediately.
$TPIV solid bottom building.
Gottlieb says Pharmas with approved NDA deliberately hold back.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136602627&txt2find=Troxyca
Under FDA Commissioner Margaret Hamburg, Pfizer's Troxyca was rejected each time, 2 or 3, primarily because of Embeda's unstable problems and re-engineering req'd over 4 years and yet Califf as a member of the voters had voted approval each time.
It didn't take long when Califf became Comissioner in 2016, to immediately approve Troxyca in Aug 2016
rocioyogi Who is Dr. Bob?
Gman24 Understandable. Califf was the one that approved Pfizer's "no-show" Troxyca in Aug 2016 following SequestOx dissing in July 2016 as well issuing the PADE. Yes it is outrageous and so obvious what he did and on the take. Connecting the dots is too easy. We are all hoping now that Gottlieb will make it right ASAP.
Dr. Robert Califf ordered it, NJ district office carried it out, and now Dr.Gottlieb has to undo it and approve $ELTP's official clearance letter ASAP.
FDA approved Fentanyl Pharmas usually market a Fentanyl patch. Also a Fentanyl Citrate solution 100 µg/mL in methanol ampules for injection by a Physician.
$TPIV Strong EOD
sharpie Agree
MA(50) is $0.088
MA(20) is $0.085
MA(30) is $0.083
$4.90 currently (formerly $3.05 )
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12363629&RcvdDate=11/7/2017&CoName=VERICEL%20CORP&FormType=10-Q&View=html
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED: September 30, 2017
Good luck and safe driving!
IMO yes. The $4.90 PPS is the updated PPS when the deal finalized.
Not a problem for me. Dominick Colangelo President & CEO, has delivered on all of his statements. For the record:
From the last CC: VCEL Q3 2017 Transcript Nov 7 2017
Not missing anything. ICT will be finalized before Dec 31, 2017 IMO as assured by CEO.
Okay now.